Improved Bottom Line

Financially, Tango’s performance improved last year. Net losses narrowed by 22 % to $101.59 million, while revenues grew 48.3 % year‑over‑year to $62.38 million. These results underpin investor interest as the company expands its clinical portfolio and seeks to translate its therapeutic developments into market traction.